Basit öğe kaydını göster

dc.contributor.authorOlgac, Asburce
dc.contributor.authorKasaplcara, Cigdem Seher
dc.contributor.authorDerinkuyu, Betul
dc.contributor.authorYuksel, Deniz
dc.contributor.authorCetinkaya, Semra
dc.contributor.authorAksoy, Ayse
dc.contributor.authorCeylaner, Serdar
dc.contributor.authorGuleray, Naz
dc.contributor.authorYesilipek, Akif
dc.contributor.authorAydin, Hatil Ibrahim
dc.date.accessioned2022-08-17T11:34:00Z
dc.date.available2022-08-17T11:34:00Z
dc.date.issued2021
dc.identifier.issn0334-018Xen_US
dc.identifier.urihttp://hdl.handle.net/11727/7370
dc.description.abstractObjectives: X-linked adrenoleukodystrophy (X-ALD), is a peroxisomal inborn error of metabolism caused due to the loss of function variants of ABCD1 gene that leads to accumulation of very long chain fatty acids (VLCFAs) in several tissues including the neurological system. Childhood cerebral X-ALD (CCALD) is the most common and severe form of X-ALD, if left untreated. Allogenic hematopoietic stem cell transplantation (HSCT) is the only available therapy that halts neurological deterioration in CCALD. We present 12 patients with several subtypes of X-ALD that were followed-up in a single center. Methods: Data of 12 patients diagnosed with X-ALD were documented retrospectively. Demographics, age of onset, initial symptoms, endocrine and neurological findings, VLCFA levels, neuroimaging data, molecular genetic analysis of ABCD1 gene, and disease progress were documented. Results: Mean age of initiation of symptoms was 7.9 years and mean age of diagnosis was 10.45 years. Eight patients had the CCALD subtype, while two had the cerebral form of AMN, one had the adult form of cerebral ALD, and one patient had the Addison only phenotype. The most common initial symptoms involved the neurological system. Loes scores varied between 0 and 12. Seven patients with CCALD underwent HSCT, among them three patients died. The overall mortality rate was 25%. Conclusions: Patients with X-ALD should be carefully followed up for cerebral findings and progression, since there is no genotype-phenotype correlation, and the clinical course cannot be predicted by family history. HSCT is the only available treatment option for patients with neurological deterioration.en_US
dc.language.isoengen_US
dc.relation.isversionof10.1515/jpem-2021-0032en_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectABCD1 geneen_US
dc.subjectLoes scoreen_US
dc.subjectvery long chain fatty acidsen_US
dc.subjectX linked adrenoleukodystophyen_US
dc.titleRetrospective evaluation of patients with X-linked adrenoleukodystrophy with a wide range of clinical presentations: a single center experienceen_US
dc.typearticleen_US
dc.relation.journalJOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISMen_US
dc.identifier.volume34en_US
dc.identifier.issue9en_US
dc.identifier.startpage1169en_US
dc.identifier.endpage1179en_US
dc.identifier.wos000694009200012en_US
dc.identifier.scopus2-s2.0-85109078837en_US
dc.contributor.pubmedID34162029en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergien_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster